PROCEPT BioRobotics makes robotic systems that use imaging and a waterjet to remove prostate tissue, mainly for hospitals. PRCT reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | Barclays | Initiated | Buy | |
| Aug 5 | TD Cowen | Maintained | Buy | |
| Aug 5 | Piper Sandler | Maintained | Buy | |
| Aug 5 | Evercore ISI Group | Target lowered | Buy | |
| Jul 28 | UBS | Assumed coverage | Hold |
Whale Options Flow
90DNo whale options trades in PRCT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRCT is in one of them and how their past PRCT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PRCT in an article yet. Here's the latest on the wider market.
About PROCEPT BioRobotics
PROCEPT BioRobotics makes surgical robots used to treat benign prostatic hyperplasia, a common condition in which the prostate gland enlarges and is not cancerous. Its AquaBeam and HYDROS robotic systems use a disposable handpiece, real time imaging and a waterjet that removes prostate tissue without heat. The company sells mainly to hospitals in the United States, with some sales through distribution partners, ambulatory surgery centers and leasing companies, and it sells to customers in other countries through its sales team and distribution partners. It is based in San Jose, California.
- Headquarters
- San Jose, CA